Key points GLP-1 is a hormone that increases insulin release and prevents the release of too much glucagon, helping manage blood glucose levels in individuals with type 2 diabetes GLP-1 receptor agonists, such as liraglutide and semaglutide, effectively reduce blood glucose levels Semaglutide is more effective than liraglutide at reducing blood sugar levels Tirzepatide is a newer GLP-1 receptor agonist that also mimics the actions of another hormone called GIP, which can also reduce blood sugar levels A randomised controlled trial showed that tirzepatide led to more significant blood sugar reductions than semaglutide across three doses Tirzepatide may be more effective than semaglutide at higher doses, but this needs further investigation Liraglutide and semaglutide are available in the UK and the US, while tirzepatide is only available in the US but is likely to be approved in the UK soon
Use a social account for faster login or easy registration
If you take just IPAM, it is not going to work
Does cancer risk affect health-related quality of life in patients with Barretts esophagus
Future research will determine whether GLP-1 drugs can become a mainstay in treating neurological and psychiatric conditions alongside traditional therapies
Serve over mixed greens with a quarter cup of pre-cooked quinoa (keep a batch in the fridge)